Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Powderly

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|January 24, 2006
Clinical perspectives of emerging pathogens in bleeding disordersChristopher A Ludlam, William G Powderly, Samuel Bozzette, et al.
Therapeutic Advances in Infectious Disease|April 29, 2025
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trialAlfredo J Mena Lora, Kimi Enders, Huimin Wu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVKathleen Squires, Adriano Lazzarin, José M Gatell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesLuis Ostrosky-Zeichner, John H Rex, Peter G Pappas, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2020
Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and IndustryAngel Velarde, Kirk Douglas Najera, Hiram Gay, et al.
AIDS (London, England)|May 7, 2009
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentRichard H Haubrich, Sharon A Riddler, A Gregory DiRienzo, et al.
Journal of Clinical Pharmacology|June 9, 2025
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM)Stephen J Balevic, Daniel Gonzalez, P Brian Smith, et al.
Annals of Epidemiology|March 11, 2022
SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis CountyCharles W Goss, Brett B Maricque, Victoria V Anwuri, et al.
CHEST Critical Care|November 29, 2024
Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM): A Secondary Data AnalysisAnne M Lachiewicz, Miloni Shah, Tatyana Der, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|January 24, 2006
Clinical perspectives of emerging pathogens in bleeding disordersChristopher A Ludlam, William G Powderly, Samuel Bozzette, et al.
Therapeutic Advances in Infectious Disease|April 29, 2025
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trialAlfredo J Mena Lora, Kimi Enders, Huimin Wu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2004
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIVKathleen Squires, Adriano Lazzarin, José M Gatell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesLuis Ostrosky-Zeichner, John H Rex, Peter G Pappas, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2020
Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and IndustryAngel Velarde, Kirk Douglas Najera, Hiram Gay, et al.
AIDS (London, England)|May 7, 2009
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentRichard H Haubrich, Sharon A Riddler, A Gregory DiRienzo, et al.
Journal of Clinical Pharmacology|June 9, 2025
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM)Stephen J Balevic, Daniel Gonzalez, P Brian Smith, et al.
Annals of Epidemiology|March 11, 2022
SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis CountyCharles W Goss, Brett B Maricque, Victoria V Anwuri, et al.
CHEST Critical Care|November 29, 2024
Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM): A Secondary Data AnalysisAnne M Lachiewicz, Miloni Shah, Tatyana Der, et al.
Pageof 15